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Hypomethylation of HOXA4 
promoter is common in Silver-
Russell syndrome and growth 
restriction and associates with 
stature in healthy children
Mari Muurinen1, Katariina Hannula-Jouppi1,2, Lovisa E. Reinius3, Cilla Söderhäll3,4, Simon 
Kebede Merid5, Anna Bergström5,7, Erik Melén5,6,7, Göran Pershagen5,7, Marita Lipsanen-
Nyman8, Dario Greco9,10 & Juha Kere  1,3,11
Silver-Russell syndrome (SRS) is a growth retardation syndrome in which loss of methylation on 
chromosome 11p15 (11p15 LOM) and maternal uniparental disomy for chromosome 7 [UPD(7)
mat] explain 20–60% and 10% of the syndrome, respectively. To search for a molecular cause for the 
remaining SRS cases, and to find a possible common epigenetic change, we studied DNA methylation 
pattern of more than 450 000 CpG sites in 44 SRS patients. Common to all three SRS subgroups, we 
found a hypomethylated region at the promoter region of HOXA4 in 55% of the patients. We then 
tested 39 patients with severe growth restriction of unknown etiology, and found hypomethylation of 
HOXA4 in 44% of the patients. Finally, we found that methylation at multiple CpG sites in the HOXA4 
promoter region was associated with height in a cohort of 227 healthy children, suggesting that HOXA4 
may play a role in regulating human growth by epigenetic mechanisms.
Silver-Russell syndrome is an imprinting disorder characterized by severe pre-and postnatal growth retardation 
and typical clinical features, including relative macrocephaly, protruding forehead, body asymmetry and feeding 
difficulties1. Imprinting disorders affect the function of genes that are normally expressed predominantly or solely 
from one parental chromosome. Chromosomal abnormalities or changes in DNA methylation level can alter 
imprinted gene dosage and lead to phenotypes affecting growth or neurological functioning2. Opposite changes 
in the same imprinted genomic regions can lead to opposite growth phenotypes, such as growth restriction in 
SRS and overgrowth in Beckwith-Wiedemann syndrome (BWS), caused by hypo- and hypermethylation, respec-
tively, of the imprinted H19-IGF2 region in 11p15 (H19/IGF2:IG-DMR) in a proportion of the cases3. SRS is a 
heterogeneous syndrome both in phenotype and in molecular etiology, but severe growth retardation is a central 
feature shared by the patients.
SRS patients can be divided into three subgroups based on their molecular etiology: maternal uniparental 
disomy of chromosome 7 (UPD(7)mat), loss of methylation on chromosome 11p15, (11p15 LOM; also known 
as hypomethylation of H19/IGF2:IG-DMR or H19 hypomethylation), and clinical SRS without any of these 
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molecular findings. Approximately 10% of SRS patients have UPD(7)mat and 20–60% of SRS patients have 11p15 
LOM4–10. Duplications and deletions at 11p15 affect <1% of SRS patients and even other molecular changes, such 
as UPD of chromosome 11 have been detected in single cases3. The remaining cases can be designated clinical 
SRS, which make up 30–70% of the SRS patients.
As all SRS patients share the same clinical diagnosis, while a substantial amount of patients test negative for 
molecular diagnosis, we hypothesized that there might occur further epigenetic changes that all subgroups of SRS 
share in common. To search for such genes or regions, we analyzed 44 SRS patients for methylation changes by 
the genome-wide Illumina Infinium HumanMethylation450K BeadChip assay that provides quantitative methyl-
ation data at more than 450 000 single CpG sites. In addition, we evaluated associations between the found meth-
ylation changes and severe growth restriction of unknown etiology (SGR), as well as growth in healthy children.
Results
Genome-wide methylation analysis pinpointed HOXA4 hypomethylation as a common epi-
genetic change among SRS subgroups. We used the Infinium HumanMethylation450K BeadChip 
(Illumina) to identify shared methylation changes in the three different SRS subgroups. We used a filtering 
approach (Fig. 1) to search for areas that were significantly differentially methylated in all subgroups compared 
to controls over a stretch of consecutive CpGs. In the first stage of filtering (filter 1), altogether 13,226 CpGs 
were found, in which the differential methylation between each of the three SRS groups compared to controls 
reached the empirical Bayes significance (nominal p-value < 0.05). We then chose regions that had at least three 
consecutive significant CpGs for all subgroups and discarded CpGs in which the methylation level of different 
groups varied to opposite directions in comparison to the controls (filter 2). This filtering process substantially 
narrowed down the potential areas and resulted in 92 CpGs located in 26 genes or intergenic loci on 13 different 
chromosomes (Supplementary Table 1). Of these CpGs, 66 showed only small differences in median Beta-value 
(<0.02) between each of the subgroups and controls. Altogether 16 CpGs showed median Beta-value differences 
>0.05 (5% absolute methylation level) for all three subgroups. Two of the 16 CpGs were located in an intergenic 
region on 5p15.33 and 14 were located in the HOXA4 gene region on 7p15.2. HOXA4 was the only area that 
showed at least 5% median methylation difference for all subgroups vs. controls for at least three consecutive 
significant CpGs. In total, HOXA4 showed 12 consecutive probes with such differences. The differences for the 
individual groups in these 12 CpGs were also larger than with any other CpGs, ranging from 6.8–25% in UPD(7)
mat, 7.1–21% in clinical SRS and 5.0–11% in 11p15 LOM patients. As a result of the filtering process of genome-
wide methylation data, HOXA4 emerged as a specific candidate for further study.
HOXA4 methylation levels differ among subgroups and are lowest near the HOXA4 transcrip-
tion start site. All three SRS subgroups showed hypomethylation throughout the HOXA4 region identified 
by filtering when comparing median methylation levels relative to controls (Fig. 2). This differentially methylated 
area included two stretches of consecutive CpGs: from cg11532431 to cg14359292 (chr7:27169674–27170892 in 
GRCh37/hg19 assembly), and from cg24169822 to cg11908057 (chr7:27170994–27171154). Localized between 
these stretches, cg25952581 (at chr7:27170961) did not reach the empirical Bayes significance for differential 
methylation between controls and 11p15 LOM group (p = 0.082), but clinical SRS and UPD(7)mat had signifi-
cant methylation differences (p = 0.013 and p < 0.001 respectively), and the methylation pattern was similar to 
the pattern of other CpGs in the region. P-values for differential methylation between subgroups and controls 
Figure 1. Filtering for common differentially methylated regions in SRS patients.
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for all HOXA4 CpGs included in our filtering are shown in Table 1. For the majority of the CpGs, the median 
methylation level was lowest in the UPD(7)mat group, followed by clinical SRS, 11p15 LOM, and controls in 
ascending order. The methylation level of the single UPD(7)pat sample was higher than controls for most of the 
CpGs. Figure 3 shows examples of methylation levels at four individual CpG sites, where methylation level of 
Figure 2. HOXA4. Median methylation levels of SRS subgroups relative to controls (1). Boundaries of the 
region in which HOXA4 CpGs are hypomethylated in SRS groups relative to controls are marked with two 
dashed vertical lines.
Coordinates in 







27168609 cg02022102 N_Shore 0,1337 0,3379 0,0345
27168688 cg03982801 N_Shore 0,4355 0,2119 0,8381
27168780 cg02706018 N_Shore 0,9538 0,3056 0,5738
27168962 cg09574499 N_Shore 0,8489 0,2095 0,4154
27169208 cg14042889 N_Shore 0,6536 0,8850 0,6749
27169674 cg11532431 CELL TYPE Island 0,0011 0,0013 8,2E-06
27169740 cg00562553 Island 0,0052 0,0037 0,0002
27170241 cg22997113 PROMOTER Island 0,0006 0,0001 1,5E-06
27170313 cg04317399 PROMOTER Island 0,0309 0,0030 4,1E-05
27170388 cg07317062 PROMOTER Island 0,0073 0,0014 8,4E-06
27170394 cg19142026 PROMOTER Island 0,0061 0,0005 7,3E-06
27170412 cg11410718 PROMOTER Island 0,0037 0,0004 3,3E-06
27170717 cg17457637 PROMOTER S_Shore 0,0349 0,0011 1,4E-05
27170819 cg06942814 PROMOTER S_Shore 0,0116 0,0004 1,9E-05
27170832 cg08657492 PROMOTER S_Shore 0,0063 0,0001 4,4E-06
27170880 cg04321618 PROMOTER S_Shore 0,0172 0,0009 9,7E-06
27170892 cg14359292 PROMOTER S_Shore 0,0125 0,0001 9,8E-07
27170961 cg25952581 PROMOTER S_Shore 0,0818 0,0125 0,0002
27170994 cg24169822 PROMOTER S_Shore 0,0120 0,0005 5,4E-06
27171051 cg17591595 PROMOTER S_Shore 0,0371 0,0006 0,0033
27171154 cg11908057 S_Shore 0,0108 0,0001 0,0031
27171203 cg25967031 S_Shore 0,0804 0,0035 0,0167
27171213 cg15196806 S_Shore 0,0526 0,0173 0,0674
27171391 cg15624376 S_Shore 0,8751 0,8147 0,2402
27171401 cg20161965 S_Shore 0,0634 0,2399 0,0240
Table 1. P-values for differential methylation for SRS subgroups (11p15 LOM, clinical SRS, UPD(7)mat) 
compared to controls for all HOXA4 CpGs that passed quality control and were included in the filtering process 
of Illumina 450 K BeadChip assay data. Regulatory feature group as indicated by Illumina is shown in column 
“Regulatory”: “PROMOTER” = Promoter_Associated, “CELL TYPE” = Unclassified_Cell_type_specific. 
Relation to UCSC CpG island chr7:27169572-27170638 is shown in column “CGI”.
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most SRS patients fell below -2 SD and UPD(7)pat remained within the range of the control group’s methylation 
level. Some SRS patients showed extremely low hypomethylation patterns and were hypomethylated even as low 
as 8 SD below the mean of the control group at cg22997113.
The identified differentially methylated area of HOXA4 was located in the promoter region and co-localized 
with the CpG island at chr7:27169573–27170638. Approximately half of the differentially methylated CpGs were 
located within the CpG island and the rest within the proximal CpG island shore. According to SwitchGear 
Genomics transcription start sites, the HOXA4 TSS is at chr7:27170399 and according to FANTOM5, at 
chr7:27170364–27170377 in the hg19 build (GRCh37/hg19 assembly). Cg19142026 at position chr7:27170394, 
the CpG with lowest relative median methylation of the HOXA4 differentially methylated area for all SRS sub-
groups, was within 5-17 bp, respectively, of the TSS.
HOXA4 hypomethylation frequency was highest for UPD(7)mat, followed by clinical SRS and 
11p15 LOM patients. While group results showed the trend that UPD(7)mat patients had the lowest 
median level of methylation for CpGs in the HOXA4 differentially methylated area, followed by the clinical SRS 
and 11p15 LOM groups, the methylation level varied between individuals within each subgroup. Figure 4(a) 
shows hypomethylation of individual SRS patients for CpGs in the HOXA4 differentially methylated area. The fre-
quency of HOXA4 hypomethylation was highest for UPD(7)mat patients at 80%, followed by clinical SRS at 62% 
and 11p15 LOM group at 38%, when hypomethylation for an individual patient was defined by at least two-thirds 
of the CpGs being hypomethylated (<−2 SD). In addition to the patients that were hypomethylated in majority 
of the CpGs in the HOXA4 area, three 11p15 LOM patients and two clinical SRS patients had hypomethylation 
in at least one-third of the HOXA4 CpGs, demonstrating a partial deviation from normal methylation status in 
the area.
Shared molecular etiology for SRS patients. Analysis of the methylation data of HOXA4 region stud-
ied by the Illumina assay revealed that altogether 24 (55%) of the SRS patients were hypomethylated in at least 
two-thirds of the CpG sites at HOXA4 differentially methylated area. Often both UPD(7)mat and HOXA4 hypo-
methylation, or HOXA4 hypomethylation and 11p15 LOM occurred in the same individual, as seen in Fig. 4(b). 
Either 11p15 LOM, UPD(7)mat, HOXA4 hypomethylation or a combination of two changes was found in 39 out 
of 44 SRS patients (89%). Only 5 patients (11%) were left without a molecular change defined by the chosen cri-
teria. In two of these patients, we observed partial hypomethylation in the HOXA4 differentially methylated area.
Frequency of 11p15 LOM was higher than previously tested. After initial analysis of our 44 SRS 
patients, we observed that more individuals had 11p15 LOM than had previously been identified. 15 of our 21 
Figure 3. Methylation level at HOXA4 cg22997113 (a), cg11410718 (b), cg08657492 (c) and cg04321618 (d). 
Individuals within each group are represented in ascending order of methylation. Dashed line represents -2 
standard deviations of the arithmetic mean of control group methylation level.
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11p15 LOM SRS patients had been previously found hypomethylated with a restriction site-specific methylation 
method11. Of the six patients that had previously not been found hypomethylated, two had not been tested and 
four had been tested but found negative. Supplementary Table 2 summarizes our result, indicating that 21 of our 
patients had clear methylation changes in this area with at least two-thirds of the 36 CpGs hypomethylated (below 
-2 SD of the controls) in the region.
EpiTYPER methylation assay revealed HOXA4 hypomethylation in patients with severe 
growth restriction of unknown etiology (SGR). We used the Sequenom EpiTYPER method to assay 
the methylation level of the HOXA4 promoter region in order to validate results from the Illumina genome-wide 
methylation study and to study a group of children with SGR. The participants included 44 SRS patients, 16 
controls and 39 children with SGR. The EpiTYPER assay spanned chr7:27170191–27170313, overlapping the 
area with significant methylation differences in the genome-wide methylation study. One CpG, cg04317399 at 
chr7:27170313, was covered by both Illumina 450 K and EpiTYPER, here named HOXA_F6_CpG_16. Analysis 
showed a strong correlation between the two methods, R2 = 0.86. (Supplementary Figure 1). Methylation levels 
of four different CpG sites (HOXA4F6CpG1, HOXA4F6CpG12.13.14, HOXA4F6CpG15, HOXA4F6CpG16) 
were measured for all participants. Statistically significant differences between the groups were determined by 
one-way ANOVA (HOXA4F6CpG1: F(4,92) = 10.831, p < 0.001; HOXA4F6CpG12.13.14: F(4, 91) = 11.549, 
p < 0.001; HOXA4F6CpG15: F(4,92) = 9.268, p < 0.001; HOXA4F6CpG16: F(4, 92) = 7.556, p < 0.001). Post hoc 
comparisons using 2-sided Dunnett t-tests indicated that the mean methylation levels of 11p15 LOM, UPD(7)
mat, clinical SRS and SGR groups were statistically significantly different from the mean of the controls at all four 
studied sites (Fig. 5). The largest mean difference (I-J = −0.249, p = 3.389 × 10−7) was observed between clinical 
SRS (I) and controls (J) at HOXA4F6CpG12.13.14. Also, an analysis of individual SGR patients showed that 44% 
(17/39) of the patients were hypomethylated for at least two-thirds of the CpGs in the HOXA4 promoter region 
at chr7: 27170191–27170313. Supplementary Table 3 shows individual methylation status of all SRS and SGR 
patients studied with the EpiTYPER assay. Thus, HOXA4 hypomethylation was not limited to SRS patients, but 
also implicated in patients with SGR.
Methylation level of HOXA4 cg11908057 correlates with height in healthy children. We stud-
ied correlation of methylation levels of HOXA4 and height of altogether 227 healthy children from the BAMSE 
(Swedish abbreviation for Children, Allergy, Milieu, Stockhom, Epidemiology) cohort, a birth cohort of chil-
dren born between 1994 and 1996 in Stockholm, Sweden. Methylation levels were measured with Infinium 
HumanMethylation450K BeadChip (Illumina)12. Sixteen CpGs of the HOXA4 differentially methylated area were 
studied. We observed a statistically significant correlation between the methylation level of one of the HOXA4 
differentially methylated CpGs, cg11908057, and height at four years of age (r = 0.142, n = 227, p = 0.033), eight 
years of age (r = 0.148, n = 225 p = 0.026) and sixteen years of age (r = 0.164, n = 200, p = 0.020) by comput-
ing Pearson correlation coefficient. As methylation data for some of the CpGs did not meet criteria for normal 
Figure 4. (a) HOXA4 CpG methylation status represented by individuals in each SRS group. Each column 
represents one patient. Green color indicates methylation level below -2SD of the controls. (b) Molecular 
changes of SRS patients, n = 44. HOXA4 hypomethylation is present in 55% of the patients.
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distribution, additional analysis using all CpGs by computing Spearman correlations revealed statistically sig-
nificant positive correlation between methylation level and height at sixteen years of age for 5 additional CpGs: 
cg04317399 (r = 0.146, n = 200, p = 0.040), cg19142026 (r = 0.139, n = 200, p = 0.050), cg04321618 (r = 0.149, 
n = 200, p = 0.036), cg14359292 (r = 0.140, n = 200, p = 0.047) and cg25952581 (r = 0.145, n = 200, p = 0.040). 
Cg11908057 demonstrated similar results as above: positive correlation was observed between methylation 
level and height at eight years of age (r = 0.140, n = 225, p = 0.036) and sixteen years of age (r = 0.147, n = 200, 
p = 0.038). Figure 6 demonstrates that the methylation level of cg11908057 in healthy children at eight years of 
age ranges from 0.69 to 0.91. This variation in methylation corresponds to a difference of 0.75 SD (or 4.5 cm) 
Figure 5. Methylation levels measured at four EpiTYPER sites for 11p15 LOM (n = 21), UPD(7)mat (n = 10), 
clinical SRS (n = 13), and SGR (n = 38, for HOXA4_F6_CpG_12.13.14 n = 37) patients compared to controls 
(n = 15). Comparisons made by 2-sided Dunnett t-tests.
Figure 6. Height measurements (in SD scale) of BAMSE individuals (n = 225) at age 8 plotted against 
meathylation level of cg11908057 measured by Illumina 450 K BeadChip assay.
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in height. In the same individuals, we studied correlation of height at age eight with some of the most strongly 
height-associated SNPs13,14 (Supplementary Table 4). In the tested SNPs, there was no significant association 
between height and genotype (Supplementary Figure 2). The results indicate that in our dataset of healthy-school 
aged children from the BAMSE cohort, the methylation level of cg11908057 at HOXA4 was better in explaining 
height variation at age eight than some of the most strongly height-associated SNPs. We also used regulomeDB15 
to study whether cg11908057 is localized in a potential regulatory protein-binding site. There was some evidence 
of binding of an enhancer of zeste homolog 2 (EZH2), a methyltransferase enzyme encoded by the EZH2 gene 
on 7q36.1. Mutations of EZH2 cause Weaver syndrome16, a pre- and postnatal overgrowth syndrome resulting in 
tall adult stature.
Methylation level of HOXA4 promoter region correlates with expression level of HOXA4 in 
blood. We used data previously published in Hannula-Jouppi et al.17, to study the correlation of HOXA4 pro-
moter region CpG methylation level and expression level of HOXA4 in blood in nine UPD(7)mat patients, one 
individual with UPD(7)pat and ten controls. The average methylation level of the HOXA4 region in SD scale 
correlated negatively with the expression level of HOXA4 in blood, as demonstrated in Fig. 7. In all differen-
tially methylated CpGs of HOXA4, we observed a statistically significant negative correlation between expression 
and methylation level by Spearman correlation analysis. The negative correlation was strongest for cg22997113 
(r = −0.81, n = 20, p = 1.40 × 10−5). Data for other CpGs is listed in Supplementary Table 5.
Discussion
We conducted a genome-wide methylation study, determining the methylation status of more than 450,000 CpG 
sites for UPD(7)mat, 11p15 LOM and clinical SRS patients, and aimed the data analysis at finding common 
methylation changes among these three groups. Initial analysis showed such changes in 26 genes or intergenic 
loci, and further analysis pinpointed HOXA4 promoter hypomethylation as a major defect in SRS. HOXA4 hypo-
methylation occurred in 55% of SRS patients, and was thus more common in our cohort than 11p15 LOM (48%) 
or UPD(7)mat (23%), and specifically, was found in eight 11p15 LOM (38%), eight UPD(7)mat (80%), and eight 
patients without any prior molecular diagnosis (62%). Furthermore, targeted methylation analysis revealed that 
HOXA4 hypomethylation was also present in children with severe growth-restriction of unknown etiology. 
Further analysis of the HOXA4 region identified multiple CpG sites where lower methylation level was associated 
with lower height in healthy school-aged children.
HOXA4 belongs to the cluster of HOXA genes located on 7p15.2. The HOXA4 hypomethylated region was 
located at chr7:27169674–27171154, with most CpGs classified as promoter-associated, and half of the CpGs 
located within the overlapping CpG island and the rest in the proximal island shore. CpG islands in somatic 
cells are usually unmethylated, and methylated promoter CpG islands are involved in long-term repression of, 
for example, imprinted genes18. Methylated CGIs are often observed near developmentally important genes, 
such as the HOX genes, and it is thought that the large numbers of potential CGI promoters within HOX loci 
may contribute to their regulation19. Relative HOXA4 methylation level was lowest for all the SRS subgroups at 
cg19142026, in close proximity to the functionally relevant transcription start site. Lower methylation level is 
often related to transcriptional activation of genes, while hypermethylation can lead to transcriptional repres-
sion16,20. We observed that hypomethylation of the HOXA4 promoter region was correlated with increased 
expression of HOXA4 in blood, when using expression data from UPD(7)mat, UPD(7)pat and controls from 
our previously published study17. Other reports have shown that hypermethylation of HOXA4 promoter region 
promotes inactivation of gene expression21,22. Altered methylation levels of the HOXA4 promoter therefore seem 
to have functional relevance by affecting gene expression.
Figure 7. HOXA4 expression level in blood measured by qPCR vs. average methylation level of HOXA4 CpGs 
in SD scale. Average methylation was calculated from all HOXA4 CpGs that showed significant differential 
methylation between all SRS groups and controls with Illumina 450 K analysis.
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Several genes within the HOXA gene cluster (HOXA2, HOXA3, HOXA4, HOXA5, HOXA6 and HOXA11) 
are predicted as maternally expressed imprinted genes23. In our previous study, HOXA4 was monoallelically 
expressed and the expression of HOXA4 was increased in whole blood of the UPD(7)mat group relative to con-
trols17, supporting the prediction of HOXA4 as a maternally expressed imprinted gene. In UPD(7)mat patients, 
HOXA4 hypomethylation can therefore be explained by the occurrence of two maternal copies of chromosome 
7, although the hypomethylation was not observed in all of the UPD(7)mat patients in our study. In 11p15 LOM 
patients, HOXA4 hypomethylation could potentially be due to multi-locus imprinting disturbance (MLID). 
MLID is reported to be present in 15–38% of 11p15 LOM patients1.
The HOX/Hox genes in human and other species are highly interesting in the context of growth disorders. 
They encode a family of transcription factors that regulate early developmental morphogenetic processes and 
are important regulators of anterior-posterior axis development24. Ten of the 39 HOX genes have been associated 
with human disorders25, such as HOXA13 with Hand-foot-genital syndrome (HFGS). Human phenotypes of the 
loss-of-function mutations in genes of the HOXA cluster include facial dysmorphisms, limb anomalies, cardiac 
defects and urogenital malformations. As the Hox genes are highly conserved, human phenotypes are very similar 
to their mouse orthologs. Hox gene knockouts in mouse affect the skeleton, primary vertebral column and slightly 
less frequently the bones of the forelimb and hindlimb. Mouse Hoxa4 loss-of-function homozygote phenotype 
showed skeletal abnormalities including partial anterior transformation of C3, posterior transformation of C7 to 
T1, presence of a C7 cervical rib and malformation of the sternum26,27. The reported Hox gene defects that often 
affect bone morphology suggest that disturbance in the normal pattern of HOXA4 methylation may also have 
relevance considering skeletal malformations in SRS patients. Interestingly, in 3-M syndrome, a growth disorder 
with a phenotype very similar to SRS, downregulation of IGF2 and upregulation of several HOX genes has been 
reported28.
Our study also included two rare samples, a UPD(7)pat and a UPD(7q31-qter)mat, in order to enable further 
investigation of the potential findings29. The methylation level of the UPD(7)pat sample was higher than the 
median methylation level of controls in most differentially methylated CpGs of HOXA4, but still within normal 
range (+/−2SD). It is interesting to note that there is no growth abnormality in this individual or other reported 
UPD(7)pat cases29–31. The segmental UPD(7q31-qter)mat was hypomethylated at 10 of the HOXA4 CpGs, even 
though HOXA4 (at 7p15.2) is located outside of the segmental UPD(7q31-qter)mat region. Further studies are 
required to better understand this observation.
Unexpectedly, we found that some of the patients that had been tested negative for 11p15 LOM previously, 
were actually positive according to our results from the genome-wide methylation study. Prickett et al. reported 
similar findings, where methylation-sensitive RFLP PCR method failed to detect 11p15 LOM patients while 
11p15 LOM was found by the Infinium Human Methylation 450 K BeadChip array32. These findings suggest that 
the genome-wide methylation assay may be more sensitive at detecting hypomethylated patients than some other 
methods.
Methylation levels may vary in different tissues and time in development. Our results are limited to methyla-
tion levels present at the time of sampling in accessible whole blood tissue. Variation in the methylation level of 
the different white blood cell populations in whole blood can complicate interpretation of whole blood methyl-
ation profiles33. In the HOXA4 region, such variation between blood cell types was not observed, and therefore 
potential differences in blood cell populations of the participants should not affect our results. Also genome-wide 
methylation studies of human blood have reported age-related modifications in specific CpGs during early child-
hood34, adulthood35 and from newborn to elderly in a meta-analysis36. Our patients included both children and 
adults, while control samples were all adults. CpGs in the HOXA4 region were, however, not among the reported 
age-modified loci, and therefore age of the participants is not expected to significantly affect our results.
Our genome-wide study of SRS patients found hypomethylation at multiple adjacent CpGs in the promoter 
region of the developmentally important HOXA4 gene. Our results indicated that HOXA4 hypomethylation was 
not specific to SRS, but was also present in children with severe growth restriction of unknown etiology. Our 
study in healthy children indicated an effect in the same direction, showing the association of hypomethyla-
tion of multiple HOXA4 CpGs with short stature. It is also worth mentioning that in HOXA3, a gene adjacent 
to HOXA4, an association between birth weight and methylation has been observed in two CpGs37, demon-
strating that the region may be important in regulating body size. We hypothesize that HOXA4 plays a role in 
growth-regulating pathways affecting SRS, related growth disorders, and also stature in general. Remarkably, the 
effect size of HOXA4 methylation in our healthy child cohort was larger than found for any of nine highly signifi-
cantly height-associated SNPs. As growth disorders share many diagnostic features, it is plausible that underlying 
genetic or epigenetic defects are shared across closely related phenotypes. Our results suggest a new candidate 
region potentially relevant in the pathogenesis of SRS, other growth disorders and growth in general.
Methods
Patients and controls. We studied 44 SRS patients. The patients included three subgroups based on molec-
ular findings: 21 patients with 11p15 LOM, 10 patients with UPD(7)mat, and 13 patients negative for both 11p15 
LOM and UPD(7)mat, assigned as clinical SRS. One paternal uniparental disomy 7 (UPD(7)pat)27 sample with-
out growth retardation was also included for comparison. One of the patients in UPD(7)mat had segmental 
UPD(7q31-qter)mat. SRS diagnoses were made based on criteria for SRS diagnosis in use at the time of evalua-
tion. Information of birth weight, birth length, postnatal growth, body asymmetry, protruding forehead, relative 
macrocephaly and feeding difficulties are listed in Supplementary Table 6. Birth length and weight for gestational 
age in SD scale are according to Finnish growth references38. Ten control blood samples were obtained from adult 
volunteers of normal height. Six additional adult control samples were from healthy blood donors31. 39 patients 
with severe growth restriction of unknown etiology (SGR) were included in a targeted analysis of HOXA4 hypo-
methylation. SGR patients had severe growth restriction but did not fulfill criteria for SRS diagnosis at the time 
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of evaluation. Information on birth length and birth weight for gestational age, and postnatal growth is listed in 
Supplementary Table 7. The majority of the SGR patients were born small for gestational age (SGA) and all of 
them had postnatal growth restriction. Methylation data from the BAMSE study12 were used to test for corre-
lation with height in healthy children. The study was approved by the Ethical Review Board of the Hospital for 
Children and Adolescents, Helsinki University Central Hospital, Helsinki, Finland (SRS and SGR patients and 
controls) and the Ethical Review Board North at Karolinska Institutet (BAMSE, blood donor controls). Informed 
consent was obtained from all study participants. Clinical investigations have been conducted according to the 
Declaration of Helsinki.
Genome-wide methylation analysis with Illumina 450K BeadChip assay. Methylation analysis 
was carried out on 44 SRS patients, one individual with UPD(7)pat, and 10 control samples. DNA from EDTA 
blood samples was extracted using the FlexiGene DNA Kit (Qiagen) according to manufacturer’s instructions. 
500 ng of DNA was bisulfite converted with the EZ-96 Methylation Kit (Zymo research corporation) according 
to the manufacturer’s instructions. Samples from 27 patients, UPD(7)pat and 10 control samples were analyzed at 
the Karolinska Institutet Bioinformatic and Expression Analysis (BEA) Core Facility, and additional 17 samples 
at the Mutation Analysis Core Facility (MAF, www.maf.ki.se). Bisulfite-treated DNA was amplified, fragmented 
and hybridized to the HumanMethylation450 BeadChip (Illumina) according to standard Illumina protocol and 
imaging was performed using Illumina iScan scanner. Additional data from similarly performed methylation 
analysis of six whole blood control samples31 produced at MAF were integrated into the analysis. Data produced 
at different facilities were comparable (data not shown). Methylation data for the BAMSE cohort had also been 
produced at MAF.
Bioinformatics analysis of the Illumina 450K BeadChip assay for SRS patients and con-
trols. The.idat files were imported in R and analyzed using the minfi package39. After quality check, the data 
were normalized using the subset-quantile within array normalization (SWAN) method40. The probes overlap-
ping with known SNPs as well as probes prone to cross-hybridization problems were removed, rendering 361,948 
CpG sites for further analysis. The M-values were extracted and the batch effects removed using the ComBat 
method41. Differentially methylated CpG sites were obtained using linear models (y~subgroup + gender) and 
pairwise comparisons with empirical Bayes as implemented in the limma package42. The differentially methylated 
CpG sites with p-value < 0.05 after Benjamini and Hochberg correction for multiple testing were considered for 
further analysis.
Filtering process for common methylation differences in genome-wide methylation data. We 
analyzed 361,948 CpGs for significant differential methylation of the UPD(7)mat, 11p15 LOM, and clinical SRS 
groups in comparison to controls. At the first stage of filtering (filter 1), we selected CpGs that showed significant 
differential methylation with a nominal p-value < 0.05 (empirical Bayes significance) for each of the three patient 
groups when compared to controls. Out of these common differentially methylated CpGs we selected those that 
fulfilled two criteria: 1) there were at least three consecutive CpGs probes with a significant difference, 2) the 
median methylation level of all of the three subgroups was either lower or higher than that of the controls (filter 
2). Consecutive CpGs were defined as occurring next to each other based on their genomic coordinates; they may 
not be representative of true consecutive CpGs in the genome, as those CpGs not included in the array as well as 
those discarded in the quality control steps were not considered. The filtering process is shown in Fig. 1.
The output list of significant CpGs that passed the filtering process was subjected to further selection by com-
paring the median methylation level of each of the subgroups to controls (Supplementary Table 1). We set a 
threshold of 5% methylation difference to further narrow down significant probes. The HOXA4 differentially 
methylated area was defined by the CpGs that passed the filtering process, comprising altogether 12 + 3 consec-
utive CpG sites.
DNA methylation analysis of HOXA4 region with EpiTYPER. We measured the methylation level 
of CpGs in the HOXA4 differentially methylated area using Sequenom EpiTYPER (Sequenom, San Diego, CA, 
USA). The analysis was carried out on 44 SRS patients, one individual with UPD(7)pat, 39 SGR patients, and 16 
controls. Bisulfite conversion with the EZ-96 Methylation Kit (Zymo research corporation), subsequent sample 
processing, and quality control were carried out at the Karolinska Institutet Mutation Analysis Core Facility. All 
assays were performed in technical duplicates, and mean of the duplicate measurements was used in the analyses. 
If one of the duplicate samples failed, then data from the one informative sample only was used. One control sam-
ple, one SGR sample and the duplicate of one 11p15 LOM SRS sample were excluded due to experimental failure. 
Normality of the data was tested using Shapiro-Wilk test of normality and homogeneity of variances by Levene’s 
statistic test. Data were further analyzed by one-way ANOVA in SPSS. Dunnett t-tests, which compare all patient 
groups against the control group, were performed post hoc.
Individual methylation level analysis and hypomethylated status. For each CpG in the HOXA4 
differentially methylated area, and each EpiTYPER site, standard deviation was calculated from the methylation 
level of the 16 control samples. Normal distribution of the control group data for each CpG (or a combination 
of CpG sites in Epityper site HOXA4_F6_CpG_12.13.14) was tested by Shapiro-Wilk normality test. Individual 
SD values for the SRS patients were calculated based on the standard deviation of the controls. A CpG site was 
considered hypomethylated when the methylation level was below -2 SD. We considered an individual patient 
generally hypomethylated at HOXA4 when the methylation level was below -2 SD for at least two-thirds of the 
CpG sites. For the Illumina assay, the treshold was 10 out of 15 CpG sites (67%), and for the EpiTYPER assay 3 
our of 4 sites (75%).
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Similarly, the patients were tested for 11p15 LOM in preliminary stages of the data analysis. We considered an 
individual patient having 11p15 LOM when at least two-thirds or 24 out of 36 (67%) CpG sites were hypometh-
ylated at chr11:2019090–2023450 in hg19 build.
Correlation analysis of HOXA4 methylation level and height in healthy children. Illumina 450 K 
methylation data from 227 healthy children from the BAMSE cohort were used to study methylation level of 
each of the HOXA4 differentially methylated area CpGs in relation to their height measurements. Both height 
measurements and DNA samples for methylation analysis were obtained at approximately age 8. Additionally, 
records of birth length, height at 4 y and height at 16 y were obtained43. Height measurements were converted 
to units of standard deviation (SD) for exact age and gender to perform correlation analysis with methylation 
values. Pearson product-moment correlation coefficient was computed for CpGs with normally distributed data. 
Normality of the data was tested with Kolmogorov-Smirnov test of normality. Additional correlation analyses 
were performed by computing Spearman rank-order correlation coefficient for all CpGs in the HOXA4 region of 
interest. The analysis was performed for each of the CpGs in comparison to birth length and height measurements 
at each age in SPSS.
Correlation analysis of HOXA4 expression and methylation level. Expression data was taken from 
our previous publication, where expression of HOXA4 in blood was studied by qPCR17. The expression data from 
nine UPD(7)mat SRS patients, one individual with UPD(7)pat and ten controls were analyzed for correlation with 
each of the 16 HOXA4 CpGs listed in Supplementary Table 5. Normality of the data was tested with Shapiro-Wilk 
test of normality. As expression data was not normally distributed, Spearman rank-order correlation analysis was 
performed. To calculate average methylation level of the 16 HOXA4 CpGs for each individual, the methylation 
levels were first converted to SD scale, based on the standard deviation of the 10 controls.
Data availability. The Illumina 450 K BeadChip methylation data discussed in this publication have been 
deposited in NCBI’s Gene Expression Omnibus44 and are accessible through GEO Series accession number 
GSE104451 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104451).
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